Summary
To study DNA topoisomerase IIα (Topo-IIα) and -β expression and regulation in human ovarian cancer, 15 ovarian tumour samples were investigated. To compare different levels of expression, the samples were screened for topo IIα and -β mRNA with Northern blotting and a quantitative reverse transcriptase polymerase chain reaction (RT-PCR) assay for Topo-IIα mRNA. Additionally, protein levels were determined with Western blotting and topoisomerase II activity levels with the decatenation assay. The results obtained were compared with each other and with the tumour volume index of the samples. In tumours with a tumour volume index ≥ 50%, the mRNA levels (as determined by Northern blotting) and protein levels for each isozyme were in accordance. Additionally, correlations were found between Topo-IIα RT-PCR data and Topo-IIα Northern blot results, and between Topo-IIα RT-PCR data and Topo-IIα protein levels. Interestingly, Topo-IIβ protein levels correlated better with Topo-II activity than Topo-IIα protein levels. In eight ovarian cystadenoma samples, no Topo-IIα protein could be found. In only three out of eight of these cystadenomas, Topo-IIβ protein could be detected. These findings suggest that Topo-IIα and Topo-IIβ protein levels are up-regulated in ovarian cancer and may indicate that Topo-IIβ is an interesting target for chemotherapy in ovarian tumours.
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Baak, J. P. A., Schipper, N. W., Wisse-Brekelmans, E. C. M., Ceelen, T. H., Bosman, F. T., van Geuns, H. & Wils, J. (1988). The prognostic value of morphometric features and cellular DNA content in cisplatin treated late ovarian cancer patients. Br J Cancer 57: 503–508.
Beck, J., Niethammer, D. & Gekeler, V. (1994). High mdr1- and mrp-, but low topoisomerase IIα-gene expression in B-cell chronic lymphocytic leukaemias. Cancer Lett 86: 135–142.
Boege, F., Andersen, A., Jensen, S., Zeidler, R. & Kreipe, H. (1995). Proliferation-associated nuclear antigen Ki-S1 is identical with topoisomerase IIα. Delineation of a carboxyterminal epitope with peptide antibodies. Am J Pathol 146: 1302–1308.
Cannistra, S. A. (1993). Cancer of the ovary. N Engl J Med 329: 1550–1559.
Chirgwin, J. M., Przybyla, A. E., MacDonald, R. J. & Rutter, W. J. (1979). Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. Biochemistry 18: 5294–5299.
Chung, T. D. Y., Drake, F. H., Tan, K. B., Per, S. R., Crooke, S. T. & Mirabelli, C. K. (1989). Characterization and immunological identification of cDNA clones encoding two human DNA topoisomerase II isozymes. Proc Natl Acad Sci USA 86: 9431–9435.
Cornarotti, M., Capranico, G., Bohm, S., Oriana, S., Spatti, G. B., Mariani, L., Ballabio, G. & Zunino, F. (1996). Gene expression of DNA topoisomerase I, IIα and IIβ and response to cisplatin-based chemotherapy in advanced ovarian carcinoma. Int J Cancer 67: 479–484.
D’Andrea, M. R., Multhaupt, H. A. D., Farber, P. A. & Fogleson, P. D. (1995). Expression of genes for DNA topoisomerase IIα and DNA topoisomerase IIβ in human tumours. Proc Am Assoc Cancer Res 36: 2690
Davies, S. L., Popert, R., Coptcoat, M., Hickson, I. D. & Masters, J. R. W. (1996). Response to epirubicin in patients with superficial bladder cancer and expression of the topoisomerase II α and β genes. Int J Cancer 65: 63–66.
De Jong, S., Zijlstra, J. G., De Vries, E. G. E. & Mulder, N. H. (1990). Reduced DNA topoisomerase II activity and drug-induced DNA cleavage activity in an adriamycin-resistant human small cell lung carcinoma cell line. Cancer Res 50: 304–309.
Drake, F. H., Hofmann, G. A., Bartus, H. F., Mattern, M. R., Crooke, S. T. & Mirabelli, C. K. (1989). Biochemical and pharmacological properties of p170 and p180 forms of topoisomerase II. Biochemistry 28: 8154–8160.
Gekeler, V., Frese, G., Noller, A., Handgretinger, R., Wilisch, A., Schmidt, H., Muller, C. P., Dopfer, R., Klingebiel, T., Diddens, H., Probst, H. & Niethammer, D. (1992). MDR1/P-glycoprotein, topoisomerase and glutathione-S-transferase pi gene expression in primary and relapsed state adult and childhood leukaemias. Br J Cancer 66: 507–517.
Harker, W. G., Slade, D. L., Parr, R. L., Feldhoff, P. W., Sullivan, D. M. & Holguin, M. H. (1995). Alterations in the topoisomerase IIα gene, messenger RNA, and subcellular protein distribution as well as reduced expression of the DNA topoisomerase IIβ enzyme in a mitoxantrone-resistant HL-60 human leukemia cell line. Cancer Res 55: 1707–1716.
Houlbrook, S., Addison, C. M., Davies, S. L., Carmichael, J., Stratford, I. J., Harris, A. L. & Hickson, I. D. (1995). Relationship between expression of topoisomerase II isoforms and intrinsic sensitivity to topoisomerase II inhibitors in breast cancer cell lines. Br J Cancer 72: 1454–1461.
Ishikawa, H., Kawano, M. M., Okada, K., Tanaka, H., Tanabe, O., Sakai, A., Asaoku, H., Iwato, K., Nobuyoshi, M. & Kuramoto, A. (1993). Expressions of DNA topoisomerase I and II gene and the genes possibly related to drug resistance in human myeloma cells. Br J Haematol 83: 68–74.
Kaufmann, S. H., Karp, J. E., Jones, R. J., Miller, C. B., Schneider, E., Zwelling, L. A., Cowan, K., Wendel, K. & Burke, P. J. (1994). Topoisomerase II levels and drug sensitivity in adult acute myelogenous leukemia. Blood 83: 517–530.
Kim, R., Hirabayashi, N., Nishiyama, M., Saeki, S., Toge, T. & Okada, K. (1991). Expression of MDR1, GST-π and topoisomerase II as an indicator of clinical response to adriamycin. Anticancer Res 11: 429–432.
Kimura, K., Saijo, M., Ui, M. & Enomoto, T. (1994). Growth state- and cell cycle-dependent fluctuation in the expression of two forms of DNA topoisomerase II and possible specific modification of the higher molecular weight form in the M phase. J Biol Chem 269: 1173–1176.
Laemmli, U. K. (1970). Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (London) 227: 680–685.
Larsson, R. & Nygren, P. (1994). Cytotoxic activity of topoisomerase II inhibitors in primary cultures of tumor cells from patients with human hematologic and solid tumors. Cancer 74: 2857–2862.
Lowry, O. H., Rosebrough, N. J., Farr, A. L. & Randall, R. J. (1951). Protein measurement with the folin–phenol reagent. J Biol Chem 193: 265–275.
Martinchick, J. C., Rahn, M. P., Jolles, C. J. & Holden, J. A. (1997). Human DNA topoisomerase II-α: immunohistochemical staining for enzyme protein in tumors of ovarian origin. Int J Oncol 10: 1229–1234.
McKenna, S. L., West, R. R., Whittaker, J. A., Padua, R. A. & Holmes, J. A. (1994). Topoisomerase II α expression in acute myeloid leukaemia and its relationship to clinical outcome. Leukemia 8: 1498–1502.
Meyer, K. N., Kjeldsen, E., Straub, T., Knudsen, B. R., Hickson, I. D., Kikuchi, A., Kreipe, H. & Boege, F. (1997). Cell cycle-coupled relocation of types I and II topoisomerases and modulation of catalytic enzyme activities. J Cell Biol 136: 775–788.
Pommier, Y. (1993). DNA topoisomerase I and II in cancer chemotherapy: update and perspectives. Cancer Chemother Pharmacol 32: 103–108.
Sandri, M. I., Hochhauser, D., Ayton, P., Camplejohn, R. C., Whitehouse, R., Turley, H., Gatter, K., Hickson, I. D. & Harris, A. L. (1996). Differential expression of the topoisomerase IIα and β genes in human breast cancers. Br J Cancer 73: 1518–1524.
Serov, S. F., Scully, R. E. & Sobin, L. H. (1973). Histological Typing of Ovarian Carcinomas, pp. 17–18, World Health Organization: Geneva
Sobre, B., Frankendal, B. & Veress, B. (1982). Importance of histological grade in the prognosis of epithelial ovarian carcinomas. Obstet Gynecol 59: 567–573.
Trimble, E. L., Arbuck, S. G. & McGuire, W. P. (1994). Options for primary chemotherapy of epithelial ovarian cancer: taxanes. Gynecol Oncol 55: S114–S121.
Turley, H., Comley, M., Houlbrook, S., Nozaki, N., Kikuchi, A., Hickson, I. D., Gatter, K. & Harris, A. L. (1997). The distribution and expression of the two isoforms of DNA topoisomerase II in normal and neoplastic human tissues. Br J Cancer 75: 1340–1346.
Van der Zee, A. G. J., Hollema, H., De Jong, S., Boonstra, H., Gouw, A., Willemse, P. H. B., Zijlstra, J. G. & De Vries, E. G. E. (1991). P-glycoprotein expression and DNA topoisomerase I and II activity in benign tumors of the ovary and in malignant tumors of the ovary, before and after platinum/cyclophosphamide chemotherapy. Cancer Res 51: 5915–5920.
Van der Zee, A. G. J., De Jong, S., Keith, W. N., Hollema, H., Boonstra, H. & De Vries, E. G. E. (1994a). Quantitative and qualitative aspects of topoisomerase I and IIα and β in untreated and platinum/cyclophosphamide treated malignant ovarian tumors. Cancer Res 54: 749–755.
Van der Zee, A. G. J., De Vries, E. G. E., Hollema, H., Kaye, S. B., Brown, R. & Keith, W. N. (1994b). Molecular analysis of the topoisomerase IIα gene and its expression in human ovarian cancer. Ann Oncol 5: 75–81.
Van der Zee, A. G. J., Hollema, H. H., De Bruijn, H. W., Willemse, P. H. B., Boonstra, H., Mulder, N. H., Aalders, J. G. & De Vries, E. G. E. (1995). Cell biological markers of drug resistance in ovarian carcinoma. Gynecol Oncol 58: 165–178.
Versantvoort, C. H. M., Withoff, S., Broxterman, H. J., Kuiper, C. M., Scheper, R. J., Mulder, N. H. & De Vries, E. G. E. (1995). Resistance associated factors in human small cell lung carcinoma GLC4sublines with increasing adriamycin resistance. Int J Cancer 61: 375–380.
Withoff, S., Smit, E. F., Meersma, G. J., Van den Berg, A., Timmer-Bosscha, H., Kok, K., Postmus, P. E., Mulder, N. H., De Vries, E. G. E. & Buys, CHCM (1994). Quantitation of DNA topoisomerase IIα messenger ribonucleic acid levels in a small cell lung cancer cell line and two drug resistant sublines using a polymerase chain reaction-aided transcript titration assay. Lab Invest 71: 61–66.
Withoff, S., De Vries, E. G. E., Keith, W. N., Nienhuis, E. F., Van der Graaf, W. T. A., Uges, D. R. A. & Mulder, N. H. (1996). Differential expression of DNA topoisomerase IIα and -β in P-gp and MRP-negative VM26, mAMSA and mitoxantrone-resistant sublines of the human SCLC cell line GLC4 . Br J Cancer 74: 1869–1876.
Zijlstra, J. G., De Vries, E. G. E. & Mulder, N. H. (1987). Multifactorial drug resistance in an adriamycin-resistant human small cell lung carcinoma cell line. Cancer Res 47: 1780–1784.
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Withoff, S., Zee, A., Jong, S. et al. DNA topoisomerase IIα and -β expression in human ovarian cancer. Br J Cancer 79, 748–753 (1999). https://doi.org/10.1038/sj.bjc.6690120
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bjc.6690120
Keywords
This article is cited by
-
Targeting of topoisomerases for prognosis and drug resistance in ovarian cancer
Journal of Ovarian Research (2016)
-
Dexrazoxane may prevent doxorubicin-induced DNA damage via depleting both Topoisomerase II isoforms
BMC Cancer (2014)
-
Topoisomerase IIα mRNA and protein expression in ovarian carcinoma: correlation with clinicopathological factors and prognosis
Modern Pathology (2009)
-
Prognostic role of topoisomerase-IIα in advanced ovarian cancer patients
British Journal of Cancer (2008)
-
ICBP90 belongs to a new family of proteins with an expression that is deregulated in cancer cells
British Journal of Cancer (2003)